|Former: Atención Farmacéutica|
|Journal edited by Rasgo Editorial since 1983|
Manuela Velázquez Prieto
EDITOR IN CHIEF
Jaime E. Poquet Jornet
Tomás Casasín Edo
Virginia Hernández Corredoira
Ramón Jódar Masanés
Juan Carlos Juárez Giménez
Volume 20 - Issue 6, November-December 2018
ANAKINRA FOR THE TREATMENT OF UNDIFFERENTIATED SYSTEMIC AUTO-INFLAMMATORY DISEASE
GARCÍA MAYO MARÍA ENCINA, GONZÁLEZ FREIRE LARA, OLIVERA FERNÁNDEZ ROSARIO, VEIGA VILLAVERDE ANA BELÉN, CRESPO DIZ CARLOS
Systemic auto-inflammatory diseases (SAID) encompass a range of rare and heterogeneous diseases of difficult diagnosis. They are result from innate dysregulation in the control of inflammatory process, leading to overproduction of proin-flammatory cytokines, such as IL-1.
The most widely used treatments are corticosteroids and colchicine, although some patients are refractory to them. The introduction of biological drugs ("biologics") designed to inhibit specific components of the inflammatory response, is presented as a therapeutic alternative in these patients.
We present the case of a man who was diagnosed with SAID and showed no response to treatment with colchicine and prednisone for whom anakinra was requested for an indication other than those approved in the summary of product characteristics (off-label).
After review of the case, the patient began treatment with subcutaneous in-fections of anakinra 100 mg every 24 hours. At thirty-five months of initiation of anakinra, the patient is still receiving the initial dosing regimen and the treatment remains both effective and well tolerated, the only adverse reaction reported being a reaction at the infection site in the first month.
ANAKINRA – AUTO-INFLAMMATORY DISEASE – IL-1